THE BIOLAN GROUP INTEGRATES THE BIOMEDICAL COMPANY DNA DATA, STRENGTHENING ITS COMMITMENT TO THE HEALTH SECTOR AND THE EXPANSION OF ITS BUSINESS

HOME » News » THE BIOLAN GROUP INTEGRATES THE BIOMEDICAL COMPANY DNA DATA, STRENGTHENING ITS COMMITMENT TO THE HEALTH SECTOR AND THE EXPANSION OF ITS BUSINESS

The company specialized in high-value genetic diagnostics will thus reinforce its highly specialized team and expand its facilities in the Gipuzcoa Science and Technology Park.

With this operation, BIOLAN reinforces its leadership in the field of health diagnostics and its highly specialized technological capabilities.

The integration of the biomedical company DNA Data, located in the Guipuzcoa Science and Technology Park, into the BIOLAN Group, specialized in food and health diagnostics, has been completed this January. This operation carried out by the biotech company from Zamudio, BIOLAN Microbiosensores, represents the culmination of the capital acquisition already started in July 2021, the result of which will allow the consolidation of an ambitious business expansion project of the Group.

DNA Data is a biomedical company specialized in the performance of genetic and biological studies for the diagnosis of diseases of genetic origin. Its scope of action is oriented towards any medical discipline, applying research, development and application of new technologies in the field of biomedicine. This clinical orientation allows DNA Data to carry out genetic studies always oriented to the diagnosis and prevention of pathologies, with a high specialization that allows DNA Data to have among its network of clients large hospitals of the public and private network at national level.

BIOLAN is a world leader in biosensorics applied to the food sector, which has also led it to extend its technology to the world of health, through its BIOLAN HEALTH division. BIOLAN develops, manufactures and markets its own products, the result of its innate commitment to R&D and continuous innovation, which has allowed it to place its innovative offer in more than 60 countries, maintain an export rate of 82%, and therefore, a significant sustained business growth in recent years, having closed 2022 with a 12% increase in turnover.

The BIOLAN Group’s commitment to DNA Data involves a considerable investment of resources in the expansion of its facilities in the Miramon Park, providing it with specialized technical equipment and incorporating the necessary professional profiles to ensure the expansion of the business. In this new venture, the General Management of DNA Data will be assumed by Carola Redondo, with an important experience in the biotechnology sector applied to health, who will lead a human team already consolidated in the company, which has amply demonstrated its professionalism, technological excellence, rigorous results, and, in short, know-how for the total satisfaction of customers. If to all this, we add the support and experience of the professional team of BIOLAN Group, sharing knowledge, experience, capabilities, sales force and markets, DNA Data is predicted a very successful future. A greater specialization in services, investment in R&D, diversification of activities and products, market expansion, … are, among others, the great challenges that the company faces with the BIOLAN Group.

In turn, the molecular technologies in which DNA Data has extensive experience will reinforce those that BIOLAN already masters, such as electrochemistry, biotechnology, lateral flow, electronics, connectivity and Big Data. As a consequence, the technological offer of innovative products and services will be clearly reinforced and will open new opportunities for the BIOLAN Group.